SEOM clinical guidelines in gestational trophoblastic disease (2017)
作者： A. Santaballa , Y. García , A. Herrero , N. Laínez , J. Fuentes
DOI: 10.1007/S12094-017-1793-0
关键词: Medicine 、 Gestational trophoblastic disease 、 Disease 、 Obstetrics 、 Chemotherapy 、 Gestational trophoblastic neoplasia
摘要: Gestational trophoblastic disease (GTD) is a rare but curable disease. Recent improvements in diagnosis and molecular biology have resulted changes staging treatment. These guidelines provide evidence-based recommendation on how to manage GTD.
springer.com
paperity.org
unirioja.es参考文章(25)
Michael J. Seckl, Neil J. Sebire, Immunohistochemical staining for diagnosis and prognostic assessment of hydatidiform moles: current evidence and future directions. Journal of Reproductive Medicine. ,vol. 55, pp. 236- 246 ,(2010)
Ross S. Berkowitz, Donald P. Goldstein, Molar Pregnancy New England Journal of Medicine. ,vol. 360, pp. 1639- 1645 ,(2009) , 10.1056/NEJMCP0900696
John R Lurain, Julian C Schink, Importance of salvage therapy in the management of high-risk gestational trophoblastic neoplasia. Journal of Reproductive Medicine. ,vol. 57, pp. 219- 224 ,(2012)
E.S. Newlands, P.J. Mulholland, L. Holden, M.J. Seckl, G.J. S. Rustin, Etoposide and Cisplatin/Etoposide, Methotrexate, and Actinomycin D (EMA) Chemotherapy for Patients With High-Risk Gestational Trophoblastic Tumors Refractory to EMA/Cyclophosphamide and Vincristine Chemotherapy and Patients Presenting With Metastatic Placental Site Trophoblastic Tumors Journal of Clinical Oncology. ,vol. 18, pp. 854- 854 ,(2000) , 10.1200/JCO.2000.18.4.854
R Agarwal, V Harding, D Short, R A Fisher, N J Sebire, R Harvey, D Patel, P M Savage, A K P Lim, M J Seckl, Uterine artery pulsatility index: a predictor of methotrexate resistance in gestational trophoblastic neoplasia. British Journal of Cancer. ,vol. 106, pp. 1089- 1094 ,(2012) , 10.1038/BJC.2012.65
P. Mapelli, G. Mangili, M. Picchio, C. Gentile, E. Rabaiotti, V. Giorgione, E. G. Spinapolice, L. Gianolli, C. Messa, M. Candiani, Role of 18F-FDG PET in the management of gestational trophoblastic neoplasia. European Journal of Nuclear Medicine and Molecular Imaging. ,vol. 40, pp. 505- 513 ,(2013) , 10.1007/S00259-012-2324-4
B You, R Harvey, E Henin, H Mitchell, F Golfier, P M Savage, M Tod, M Wilbaux, G Freyer, M J Seckl, Early prediction of treatment resistance in low-risk gestational trophoblastic neoplasia using population kinetic modelling of hCG measurements British Journal of Cancer. ,vol. 108, pp. 1810- 1816 ,(2013) , 10.1038/BJC.2013.123
Hys Ngan, H. Bender, J.L. Benedet, H. Jones, G.C. Montruccoli, S. Pecorelli, FIGO Committee on Gynecologic Oncol, Gestational trophoblastic neoplasia, FIGO 2000 staging and classification International Journal of Gynecology & Obstetrics. ,vol. 83, pp. 175- 177 ,(2003) , 10.1016/S0020-7292(03)90120-2
I. A. McNeish, S. Strickland, L. Holden, G. J.S. Rustin, M. Foskett, M. J. Seckl, E. S. Newlands, Low-Risk Persistent Gestational Trophoblastic Disease: Outcome After Initial Treatment With Low-Dose Methotrexate and Folinic Acid From 1992 to 2000 Journal of Clinical Oncology. ,vol. 20, pp. 1838- 1844 ,(2002) , 10.1200/JCO.2002.07.166
HARRIET O. SMITH, Gestational trophoblastic disease epidemiology and trends. Clinical Obstetrics and Gynecology. ,vol. 46, pp. 541- 556 ,(2003) , 10.1097/00003081-200309000-00006